The fine is in two parts.

The fine is in two parts, corresponding to $ 9,000 for certain mismanagement the blood products, including red blood cells, plasma and platelets, and $ 6,000 of non-compliance with good manufacturing practices.

The FDA said they those penalties these penalties to encourage the Red Cross, to act quickly and fix the issues involved, the agency said it recent efforts recent efforts of the Red Cross guide.Reflex that presents the first full laboratory test to KRAS, NRB and BRAF mutations Analyse to reflection Testing Service.